Novo Nordisk filed a lawsuit against telehealth company Hims & Hers Health on February 5, 2026, accusing the firm of mass‑producing and selling unapproved copies of its Wegovy weight‑loss drug. The complaint alleges that Hims & Hers has been offering a compounded semaglutide pill for $49 in the first month, a price that is far below the $149 per month for the branded Wegovy. The lawsuit claims the compounded product is unapproved, may contain impurities, and violates FDA regulations, while also infringing on Novo’s intellectual property and undermining its pricing strategy in the U.S. obesity market.
The legal action follows a June 2025 termination of a collaboration between Novo Nordisk and Hims & Hers, which was ended over similar concerns about deceptive promotion and illegal mass compounding of Wegovy. The June decision highlighted the growing tension between the two companies and set the stage for the February lawsuit, which now seeks injunctive relief and damages to protect patient safety and Novo’s brand integrity.
Novo’s CEO, Mike Doustdar, has repeatedly warned that compounded semaglutide pills pose a significant risk to patients and threaten Novo’s market share. In a statement accompanying the lawsuit, a Novo spokesperson said, “The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety. Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the U.S. drug approval framework.”
The lawsuit arrives shortly after Novo’s Q4 2025 earnings release, which reported earnings per share of $1.01–$1.02 versus analyst expectations of $0.89–$0.90, a beat of $0.12–$0.13. Revenue of $12.43–$12.53 billion also topped estimates of $11.97–$11.99 billion. The earnings beat was driven by strong demand for the oral Wegovy pill, which launched in the U.S. earlier this year, and by cost controls that offset a 4% revenue decline. However, the company warned that 2026 guidance would see adjusted sales growth of –5% to –13% at constant exchange rates, reflecting pricing headwinds, intensified competition from Eli Lilly and compounded drug providers, and a slowdown in growth momentum.
The FDA has issued warnings about the safety of unapproved semaglutide products, noting that compounded drugs do not undergo the same rigorous review as FDA‑approved medications. The agency has also taken action at the border to stop the import of unapproved GLP‑1 active pharmaceutical ingredients, underscoring the regulatory risk that Novo is seeking to mitigate through the lawsuit.
Market reaction to the lawsuit was muted compared to the sharp decline that followed the earnings announcement, as investors focused on the broader pricing and competitive pressures. The lawsuit, however, signals Novo’s aggressive defense of its GLP‑1 franchise and its willingness to use legal and regulatory tools to protect its market position in a rapidly evolving obesity and diabetes landscape.
The legal action underscores the broader challenge Novo faces from compounded drug providers that offer cheaper alternatives, potentially eroding Novo’s pricing power and market share. By pursuing litigation, Novo aims to deter similar practices and reinforce the importance of FDA approval for safety and efficacy, thereby protecting both patients and its commercial interests.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.